Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENAISSANCE 4: Dexmecamylamine as Adjunct in MDD
NCT01153347Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2010
- Primary completion
- Jan 2012
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of dexmecamylamine in major depressive disorder (MDD), sponsored by AstraZeneca. Started Jun 2010; status: completed.
02
Drugs
dexmecamylamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01153347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01153347.